Lifecore Biomedical, Inc.
LFCR
$6.14
-$0.04-0.65%
| 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | 11/26/2023 | |
|---|---|---|---|---|---|
| Net Income | 80.30% | 106.58% | 112.07% | 82.58% | 8.87% |
| Total Depreciation and Amortization | -13.90% | -26.18% | -37.53% | -31.55% | 3.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -79.59% | -127.39% | -134.03% | -98.01% | -32.27% |
| Change in Net Operating Assets | -132.16% | -7.96% | -118.40% | -105.39% | -74.16% |
| Cash from Operations | 101.68% | 131.42% | 100.37% | 31.09% | -425.44% |
| Capital Expenditure | 37.47% | 28.63% | 15.26% | 11.56% | -26.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 101.81% | 119.91% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -46.74% | -71.60% | -278.36% | -24.56% | 56.06% |
| Total Debt Issued | -13.83% | -16.98% | -17.56% | 441.39% | 355.43% |
| Total Debt Repaid | 11.02% | 17.22% | 17.33% | -307.19% | -1,665.44% |
| Issuance of Common Stock | 3,192.96% | -99.98% | -85.52% | -85.52% | -85.52% |
| Repurchase of Common Stock | -256.33% | -61.86% | 66.37% | 86.31% | 37.50% |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 218.50% | 178.83% | 178.83% | 157.74% | -827.91% |
| Cash from Financing | -24.90% | -85.36% | -81.09% | -4.60% | -13.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 272.73% | -170.63% | -160.92% | -88.78% | -172.53% |
